Record revenue and double-digit adjusted EBITDA growth were driven by strong industrial and consumer demand, margin expansion, and strategic portfolio actions. Guidance for 2026 remains confident, with continued investment in lab capacity and resilience across key end markets.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.